Wound Management Technologies inks marketing agreement with Pharma Technology International

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today an agreement with Pharma Technology International, LLC (Pharma Tech) to market, distribute and sell the company's wound care products in the Middle East. Pharma Tech is a joint venture between A&Z Pharmaceutical and BioPharma Management Technologies, Inc., a company recently acquired by Wound Management Technologies.

The initial focus will be on Wound Management Technologies' major product, CellerateRx(R), which is used in the management of pressure ulcers, traumatic wounds, diabetic ulcers, first and second degree burns, venous stasis ulcers, ulcers due to arterial insufficiency and superficial wounds. CellerateRx's patented collagen fragments, which are a fraction of the size of the native collagen molecules and particles found in other products, deliver the benefits of collagen to the body immediately.

This exclusive agreement will require Pharma Tech, LLC to sell a minimum of (USD) $500,000 of CellerateRx in the first year of the five-year agreement with a 10% increase year over year. The agreement covers 20 countries throughout the Middle East and Northern Africa.

Wound Management Technologies CEO Scott Haire said, "This agreement with Pharma Tech represents an important expansion of our sales activities by opening the strategic Middle East region. Pharma Tech has strong marketing operations and deep distribution channels, which strengthen our expectation for excellent results from this new association."